Recent findings highlight the involvement of epigenetic regulators like enhancer of zeste homolog 2 (EZH2), which has been linked to disrupted skeletal muscle differentiation and tumorigenesis in rhabdomyosarcoma, suggesting its role as a key mediator in RMS progression and as a potential therapeutic target [54]. Here, EZH2 is linked to rhabdomyosarcoma.